# EDGAR Filing Document

**Accession Number:** 0000862861
**File Stem:** 0000000000-25-010339
**Filing Date:** 2025-9
**Character Count:** 3651
**Document Hash:** 0fa7fabc7155e8565b91b8c643728dcb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-010339.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0000000000-25-010339

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250922

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALT5 Sigma Corp
- **CENTRAL INDEX KEY:** 0000862861
- **STANDARD INDUSTRIAL CLASSIFICATION:** [6221]
- **ORGANIZATION NAME:** 09 Crypto Assets
- **EIN:** 411454591
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 000-19621

**BUSINESS ADDRESS:**
- **STREET 1:** 325 E. WARM SPRINGS ROAD
- **STREET 2:** SUITE 102
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89119
- **BUSINESS PHONE:** 702-997-5968

**MAIL ADDRESS:**
- **STREET 1:** 325 E. WARM SPRINGS ROAD
- **STREET 2:** SUITE 102
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89119

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JanOne Inc.
- **DATE OF NAME CHANGE:** 20190912

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** APPLIANCE RECYCLING CENTERS OF AMERICA INC /MN
- **DATE OF NAME CHANGE:** 19930328
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-25-013104

## Text-Extract

```

                                                            September 22, 2025

Jonathan Hugh
Chief Financial Officer
ALT5 Sigma Corporation
325 E. Warm Springs Road, Suite 102
Las Vegas, Nevada 89119

       Re: ALT5 Sigma Corporation
           Preliminary Proxy Statement on Schedule 14A
           Response dated September 19, 2025
           File No. 000-19621
Dear Jonathan Hugh:

        We have reviewed your September 19, 2025 response to our comment letter
and have
the following comment.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Preliminary Proxy Statement on Schedule 14A
Proposal 1
The Issuance and Appointment Proposal, page 7

1.     We note your response to prior comment 1 regarding the    Issuance and
Appointment
       Proposal    (Proposal 1). Please revise your proxy to present the share
issuance as one
       proposal and the appointment of a second director candidate as a
separate proposal. In
       this regard, please refer to staff guidance provided in Compliance and
Disclosure
       Interpretation 101.01 Regarding Unbundling under Rule 14a-(3) Generally,
which
       explains that two separate matters are not deemed to be inextricably
intertwined
       merely because the matters were negotiated as part of a transaction with
a third party,
       nor because the matters represent terms of a contract that one or the
other of the
       parties considers essential to the overall bargain.
       We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
 September 22, 2025
Page 2

of action by the staff.

       Please contact Jimmy McNamara at 202-551-7349 or Joe McCann at
202-551-6262
with any other questions.

                                                     Sincerely,

                                                     Division of Corporation
Finance
                                                     Office of Life Sciences
cc:    Faith Charles

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._